{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:34:32Z","timestamp":1740123272061,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The prognosis of local invasive recurrence (LIR) after prior carcinoma in situ (CIS) of the breast has not been widely studied and existing data are conflicting, especially considering the specific prognosis of this entity, compared to de novo invasive breast cancer (de novo IBC) and with LIR after primary IBC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We designed a retrospective study using data from the specialized C\u00f4te d\u2019Or Breast and Gynecological cancer registry, between 1998 and 2015, to compare outcomes between 3 matched groups of patients with localized IBC: patients with LIR following CIS (CIS-LIR), patients with de novo IBC (de novo IBC), and patients with LIR following a first IBC (IBC-LIR). Distant relapse-free (D-RFS), overall survival (OS), clinical, and treatment features between the 3 groups were studied.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 8186 women initially diagnosed with IBC during our study period, we retrieved and matched 49 CIS-LIR to 49 IBC, and 46 IBC-LIR patients. At diagnosis, IBC\/LIR in the 3 groups were mainly stage I, grade II, estrogen receptor-positive, and HER2 negative. Metastatic diseases at diagnosis were higher in CIS-LIR group. A majority of patients received adjuvant systemic treatment, with no statistically significant differences between the 3 groups. There was no significant difference between the 3 groups in terms of OS or D-RFS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>LIR after CIS does not appear to impact per se on survival of IBC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10549-022-06807-w","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T09:11:58Z","timestamp":1669194718000},"page":"377-385","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognosis of local invasive relapses after carcinoma in situ of the breast: a retrospective study from a population-based registry"],"prefix":"10.1007","volume":"197","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8782-6849","authenticated-orcid":false,"given":"Samia","family":"Kada Mohammed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tienhan Sandrine","family":"Dabakuyo Yonli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Desmoulins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariane","family":"Manguem Kamga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9mentine","family":"Jankowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Martine","family":"Padeano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Loustalot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Costaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"Causeret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karine","family":"Peignaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magali","family":"Rouffiac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Coutant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Arnould","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"Ladoire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,23]]},"reference":[{"issue":"2","key":"6807_CR1","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1016\/j.clbc.2019.08.002","volume":"20","author":"B Cutuli","year":"2020","unstructured":"Cutuli B, Lemanski C, De Lafontan B, Chauvet M-P, De Lara CT, Mege A et al (2020) Ductal carcinoma in situ: a french national survey. analysis of 2125 patients. Clin Breast Cancer 20(2):e164\u2013e172","journal-title":"Clin Breast Cancer"},{"issue":"4","key":"6807_CR2","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.amjsurg.2006.06.005","volume":"192","author":"LA Lee","year":"2006","unstructured":"Lee LA, Silverstein MJ, Chung CT, Macdonald H, Sanghavi P, Epstein M et al (2006) Breast cancer\u2013specific mortality after invasive local recurrence in patients with ductal carcinoma-in-situ of the breast. Am J Surg 192(4):416\u2013419","journal-title":"Am J Surg"},{"issue":"32","key":"6807_CR3","doi-asserted-by":"publisher","first-page":"4054","DOI":"10.1200\/JCO.2013.49.5077","volume":"31","author":"M Donker","year":"2013","unstructured":"Donker M, Liti\u00e8re S, Werutsky G, Julien J-P, Fentiman IS, Agresti R et al (2013) Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase iii trial. J Clin Oncol 31(32):4054\u20134059","journal-title":"J Clin Oncol"},{"issue":"4","key":"6807_CR4","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S0039-6109(16)45185-6","volume":"70","author":"MD Lagios","year":"1990","unstructured":"Lagios MD (1990) Duct carcinoma in situ: pathology and treatment. Surg Clin North Am 70(4):853\u2013871","journal-title":"Surg Clin North Am"},{"issue":"9","key":"6807_CR5","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/0959-8049(95)00283-O","volume":"31","author":"MJ Silverstein","year":"1995","unstructured":"Silverstein MJ, Barth A, Poller DN, Gierson ED, Colburn WJ, Waisman JR et al (1995) Ten-year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast. Eur J Cancer 31(9):1425\u20131427","journal-title":"Eur J Cancer"},{"issue":"4","key":"6807_CR6","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/S0360-3016(02)02834-1","volume":"53","author":"B Cutuli","year":"2002","unstructured":"Cutuli B, Cohen-Solal-le Nir C, de Lafontan B, Mignotte H, Fichet V, Fay R et al (2002) Breast-conserving therapy for ductal carcinoma in situ of the breast: the French cancer centers\u2019 experience. Int J Radiat Oncol Biol Phys 53(4):868\u2013879","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"6807_CR7","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1200\/JCO.1998.16.4.1367","volume":"16","author":"MJ Silverstein","year":"1998","unstructured":"Silverstein MJ, Lagios MD, Martino S, Lewinsky BS, Craig PH, Beron PJ et al (1998) Outcome after invasive local recurrence in patients with ductal carcinoma in situ of the breast. J Clin Oncol 16(4):1367\u20131373","journal-title":"J Clin Oncol"},{"issue":"4","key":"6807_CR8","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.amjsurg.2004.06.034","volume":"188","author":"L Romero","year":"2004","unstructured":"Romero L, Klein L, Ye W, Holmes D, Soni R, Silberman H et al (2004) Outcome after invasive recurrence in patients with ductal carcinoma in situ of the breast. Am J Surg 188(4):371\u2013376","journal-title":"Am J Surg"},{"issue":"2","key":"6807_CR9","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s10549-016-3894-9","volume":"158","author":"V Sopik","year":"2016","unstructured":"Sopik V, Iqbal J, Sun P, Narod SA (2016) Impact of a prior diagnosis of DCIS on survival from invasive breast cancer. Breast Cancer Res Treat 158(2):385\u2013393","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"6807_CR10","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3322\/caac.21393","volume":"67","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, Weaver DL, Winchester DJ, Hortobagyi GN (2017) Breast cancer\u2014major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67(4):290\u2013303","journal-title":"CA Cancer J Clin"},{"key":"6807_CR11","doi-asserted-by":"crossref","unstructured":"Elston CW, Ellis IO.(2002) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. C. W. Elston & I. O. Ellis. Histopathology 1991; 19; 403\u2013410. Histopathology. (3A):151\u20132, discussion 152\u2013153.","DOI":"10.1046\/j.1365-2559.2002.14691.x"},{"issue":"31","key":"6807_CR12","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: american society of clinical oncology\/college of american pathologists clinical practice guideline update. J Clin Oncol 31(31):3997\u20134013","journal-title":"J Clin Oncol"},{"issue":"5","key":"6807_CR13","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/annonc\/mdv106","volume":"26","author":"S Gourgou-Bourgade","year":"2015","unstructured":"Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F et al (2015) Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). Ann Oncol 26(5):873\u2013879","journal-title":"Ann Oncol"},{"issue":"1","key":"6807_CR14","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1200\/JCO.1991.9.1.191","volume":"9","author":"JJ Shuster","year":"1991","unstructured":"Shuster JJ (1991) Median follow-up in clinical trials. J Clin Oncol Off J Am Soc Clin Oncol 9(1):191\u2013192","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"6807_CR15","unstructured":"Prise en charge du carcinome canalaire in situ \/Questions d\u2019actualit\u00e9. Recommandations et r\u00e9f\u00e9rentiels, INCa, septembre 2015\u00a9. Available from: https:\/\/www.e-cancer.fr\/Expertises-et-publications\/Catalogue-des-publications\/Prise-en-charge-du-carcinome-canalaire-in-situ-Questions-d-actualite-Rapport-integral"},{"issue":"6","key":"6807_CR16","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/1097-0142(20010315)91:6<1090::AID-CNCR1104>3.0.CO;2-D","volume":"91","author":"LJ Solin","year":"2001","unstructured":"Solin LJ, Fourquet A, Vicini FA, Haffty B, Taylor M, McCormick B et al (2001) Salvage treatment for local recurrence after breast-conserving surgery and radiation as initial treatment for mammographically detected ductal carcinoma in situ of the breast. Cancer 91(6):1090\u20131097","journal-title":"Cancer"},{"issue":"5","key":"6807_CR17","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/S0360-3016(00)01378-X","volume":"48","author":"TE Smith","year":"2000","unstructured":"Smith TE, Lee D, Turner BC, Carter D, Haffty BG (2000) True recurrence vs new primary ipsilateral breast tumor relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management. Int J Radiat Oncol 48(5):1281\u20131289","journal-title":"Int J Radiat Oncol"},{"issue":"3","key":"6807_CR18","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/0360-3016(93)90382-6","volume":"27","author":"BG Haffty","year":"1993","unstructured":"Haffty BG, Carter D, Flynn SD, Fischer DB, Brash DE, Simons J et al (1993) Local recurrence versus new primary: clinical analysis of 82 breast relapses and potential applications for genetic fingerprinting. Int J Radiat Oncol 27(3):575\u2013583","journal-title":"Int J Radiat Oncol"},{"key":"6807_CR19","doi-asserted-by":"crossref","unstructured":"Witteveen A, Kwast ABG, Sonke GS, IJzerman MJ, Siesling S. (2015) Survival after locoregional recurrence or second primary breast cancer: impact of the disease-free interval. PLoS ONE [Internet]. [cited 2020 Jul 4];10(4). Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4393268\/","DOI":"10.1371\/journal.pone.0120832"},{"issue":"1","key":"6807_CR20","first-page":"83","volume":"43","author":"C-C Yu","year":"2020","unstructured":"Yu C-C, Kuo W-L, Shen S-C, Chou H-H, Lo Y-F, Yu M-C et al (2020) Prognostic study for isolated local recurrence operated with salvage excision in hormone-receptor-positive patients with invasive breast cancer after primary breast surgery. Biomed 43(1):83\u201393","journal-title":"Biomed"},{"issue":"2","key":"6807_CR21","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1093\/annonc\/mdr129","volume":"23","author":"E Montagna","year":"2012","unstructured":"Montagna E, Bagnardi V, Rotmensz N, Viale G, Renne G, Cancello G et al (2012) Breast cancer subtypes and outcome after local and regional relapse. Ann Oncol 23(2):324\u2013331","journal-title":"Ann Oncol"},{"issue":"13","key":"6807_CR22","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.2005.04.3273","volume":"24","author":"IL Wapnir","year":"2006","unstructured":"Wapnir IL, Anderson SJ, Mamounas EP, Geyer CE, Jeong J-H, Tan-Chiu E et al (2006) Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five national surgical adjuvant breast and bowel project node-positive adjuvant breast cancer trials. J Clin Oncol 24(13):2028\u20132037","journal-title":"J Clin Oncol"},{"issue":"8","key":"6807_CR23","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/annonc\/mdg347","volume":"14","author":"M Waeber","year":"2003","unstructured":"Waeber M, Castiglione-Gertsch M, Dietrich D, Th\u00fcrlimann B, Goldhirsch A, Brunner KW et al (2003) Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23\/82) comparing tamoxifen with observation. Ann Oncol 14(8):1215\u20131221","journal-title":"Ann Oncol"},{"issue":"11","key":"6807_CR24","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1200\/JCO.2017.76.5719","volume":"36","author":"IL Wapnir","year":"2018","unstructured":"Wapnir IL, Price KN, Anderson SJ, Robidoux A, Mart\u00edn M, Nortier JWR et al (2018) Efficacy of chemotherapy for ER-negative and ER-positive isolated locoregional recurrence of breast cancer: final analysis of the CALOR trial. J Clin Oncol 36(11):1073\u20131079","journal-title":"J Clin Oncol"},{"issue":"12","key":"6807_CR25","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/j.annonc.2021.09.015","volume":"32","author":"N Harbeck","year":"2021","unstructured":"Harbeck N, Rastogi P, Martin M, Tolaney SM, Shao ZM, Fasching PA et al (2021) Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol 32(12):1571\u20131581","journal-title":"Ann Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06807-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-022-06807-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06807-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T05:28:42Z","timestamp":1672982922000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-022-06807-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,23]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["6807"],"URL":"https:\/\/doi.org\/10.1007\/s10549-022-06807-w","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"type":"print","value":"0167-6806"},{"type":"electronic","value":"1573-7217"}],"subject":[],"published":{"date-parts":[[2022,11,23]]},"assertion":[{"value":"1 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the CGFL Research Ethics Committee. CGFL has been authorized to conduct scientific research by relevant French authorities (authorization number AC-2019\u20133531).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The Cote d\u2019Or Registry has been granted an ethical approval allowing the use of the data recorded in this registry for medical studies by the National ethics committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}